A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

This Phase 1 trial is testing a combination of three drugs — ruxolitinib, steroids, and lenalidomide — in patients with multiple myeloma (a blood cancer affecting plasma cells) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You have been diagnosed with multiple myeloma, confirmed through bone marrow testing or blood/urine protein tests - Your myeloma has returned or stopped responding to prior treatments (relapsed or refractory) - Your cancer can be measured through blood, urine, or specialized lab tests - Your blood counts, kidney function, and liver function are adequate - You are in a stable enough condition to participate - You agree to use contraception if applicable **You may NOT be eligible if...** - You have not had multiple myeloma confirmed by standard criteria - Your cancer cannot be measured or monitored through standard tests - Your blood counts, kidneys, or liver are not functioning well enough - You have serious heart, lung, or other conditions that would make participation unsafe - You are pregnant or breastfeeding - You have an active, uncontrolled infection Talk to your doctor to see if this trial is right for you.